Metraipolis › archive › dc_4edcdafebf97

Guidelines for tuberculosis screening and preventive treatment among pregnant and breastfeeding women living with HIV in PEPFAR-supported countries — Europe PMC PMID:38625930

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/38625930
DOI: 10.1371/journal.pone.0296993
License (as archived): CC0-1.0
Archived: 2026-10-06T18:47:43.289Z
SHA-256 of the archived text: 60a24bdaa0acdc4cbbca84409eab9523c03fc332df785425deac1c03a5509a99
Stable URL of this page: https://metraipolis.com/documento/dc_4edcdafebf97

How to cite

Guidelines for tuberculosis screening and preventive treatment among pregnant and breastfeeding women living with HIV in PEPFAR-supported countries — Europe PMC PMID:38625930 — Europe PMC (en), https://europepmc.org/article/MED/38625930 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_4edcdafebf97 (Metraipolis archive dc_4edcdafebf97, sha256 60a24bdaa0acdc4cbbca84409eab9523c03fc332df785425deac1c03a5509a99)

BibTeX

@misc{dc4edcdafebf97,
  title = {Guidelines for tuberculosis screening and preventive treatment among pregnant and breastfeeding women living with HIV in PEPFAR-supported countries — Europe PMC PMID:38625930},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38625930},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_4edcdafebf97; sha256 60a24bdaa0acdc4cbbca84409eab9523c03fc332df785425deac1c03a5509a99},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38625930. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Tuberculosis (TB) preventive treatment (TPT) is recommended by the World Health Organization (WHO) for persons living with HIV, including pregnant and breastfeeding women. Given the President's Emergency Plan for AIDS Relief (PEPFAR)'s investment in TPT services for persons living with HIV as a strategy to prevent TB as well as uncertainty in guidelines and policy regarding use of TPT during pregnancy and the postpartum period, we conducted a review of current relevant national guidelines among PEPFAR-supported countries. Methods: Our review included 44/49 PEPFAR-supported countries to determine if TB screening and TPT are recommended specifically for pregnant and breastfeeding women living with HIV (WLHIV). National guidelines reviewed and abstracted included TB, HIV, prevention of vertical HIV transmission, TPT, and any other relevant guidelines. We abstracted information regarding TB screening, including screening tools and frequency; and TPT, including timing, regimen, frequency, and laboratory monitoring. Results: Of 44 PEPFAR-supported countries for which guidelines were reviewed, 66% were high TB incidence countries; 41% were classified by WHO as high TB burden countries, and 43% as high HIV-associated TB burden countries. We found that 64% (n = 28) of countries included TB screening recommendations for pregnant WLHIV in their national guidelines, and most (n = 35, 80%) countries recommend TPT for pregnant WLHIV. Fewer countries included recommendations for breastfeeding as compared to pregnant WLHIV, with only 32% (n = 14) mentioning TB screening and 45% (n = 20) specifically recommending TPT for this population; most of these recommend isoniazid-based TPT regimens for pregnant and breastfeeding WLHIV. However, several countries also recommend isoniazid combined with rifampicin (3RH) or rifapentine (3HP). Conclusions: Despite progress in the number of PEPFAR-supported countries that specifically include TB screening and TPT recommendations for pregnant and breastfeeding WLHIV in their national guidelines, many PEPFAR-supported countries still do not include specific screening and TPT recommendations for pregnant and breastfeeding WLHIV.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2024 (prima pubblicazione 2024-04-16).
Identificativi: PMID 38625930 · PMCID PMC11021021 · DOI 10.1371/journal.pone.0296993.
Descrittori MeSH principali: Tuberculosis; HIV Infections.
Pagina: https://europepmc.org/article/MED/38625930 — https://doi.org/10.1371/journal.pone.0296993. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T17:12:53.328Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.